Insider Sell: Michelle Lewis Sells 15,000 Shares of PACS Group I
Michelle Lewis, Chief Accounting Officer of PACS Group Inc (PACS), sold 15,000 shares of the company on July 6, 2026. This transaction brings her total ownership down to 355,338 shares. Over the past year, Lewis has sold 30,000 shares, and the company's insider transaction history shows 1 insider buy versus 8 insider sells.
PACS Group CAO Michelle Lewis sells $675k in company stock
Michelle Lewis, Chief Accounting Officer of PACS Group, Inc. (NASDAQ:PACS), sold 15,000 shares of company stock for over $675,000 in early July 2026 under a pre-arranged trading plan. These sales occurred as PACS stock traded near its 52-week high, having gained 242% in the past year, and coincided with the company's strong Q1 2026 financial performance and a significant acquisition. Following the transactions, Ms. Lewis still holds over 355,000 shares.
Director at PACS Group (PACS) awarded 4,287 RSUs vesting by 2027
PACS Group, Inc. director Patrick Hugh Conway received an equity award of 4,287 restricted stock units (RSUs), with no purchase price. These RSUs will convert into one share of Common Stock each upon vesting. The vesting condition requires Conway's continued service to the company until the earlier of July 1, 2027, or the company’s next annual meeting.
Insider Mark Hancock trims PACS Group, Inc. (PACS) stake
PACS Group director Mark Hancock sold a total of 161,068 shares of common stock across three transactions between July 1 and July 6, 2026, for approximately $7.30 million. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan. Additionally, Hancock received 4,287 restricted stock units which will vest on July 1, 2027, or the next annual meeting.
Director Taylor Leavitt awarded 4,287 RSUs at PACS Group (PACS)
PACS Group, Inc. director Taylor S. Leavitt was granted 4,287 restricted stock units (RSUs) with a vesting date on the earlier of July 1, 2027, or the next annual meeting, provided he remains in service. This award, valued at $0.00 per share, increases his direct holdings to 19,784 shares of common stock. This transaction is classified as an equity award and not an open-market stock purchase.
Mark Hancock sells PACS shares (NYSE: PACS) in multiple Form 144 filings
Mark Hancock has reported multiple proposed sales of common stock in PACS Group, Inc. (NYSE: PACS) through Form 144 filings. These filings detail transactions on several dates in June and July 2026, showing the number of shares sold and the gross proceeds for each sale. The transactions are disclosed as sales of issuer common stock by an affiliate.
Have Insiders Sold PACS Group Shares Recently?
A recent analysis of PACS Group (NYSE: PACS) insider transactions revealed that the Chief Accounting Officer sold US$600k worth of shares, and the Chief Legal Officer sold US$4.8m in the last year, both at prices below the current market value. While significant insider ownership (70%) is a positive, the pattern of selling without corresponding buying raises caution among investors. The company is profitable and growing, but the insider selling trends indicate potential valuation concerns.
Pacs Group options trading jumps to 7,248 contracts
Trading activity in Pacs Group Inc. options surged to 7,248 contracts by 1:50 p.m. New York time on Thursday, with call options dominating the activity. The January 15, 2027 $50 call alone accounted for 7,133 contracts. Pacs Group shares experienced a slight increase, and its three-month volatility dropped.
Why Is PACS Group Stock Soaring Tuesday?
PACS Group, Inc. (NYSE: PACS) stock increased over 7% on Tuesday following the announcement of its plan to acquire the operations of 34 skilled nursing facilities from Eduro Healthcare, significantly expanding its post-acute care portfolio. This acquisition includes 3,633 skilled nursing beds across multiple states, with the transaction expected to close in tranches, primarily in Q3 2026. Analysts maintain a "Strong Buy" rating with an average price target of $49.00, reinforcing the stock's bullish technical indicators and strong long-term uptrend.
Mark Hancock sells 500,000 PACS shares (PACS) for $18.9M in June 2026
Mark Hancock, an affiliate of PACS, reported the sale of 500,000 shares of PACS common stock in June 2026 through five separate transactions. These sales generated aggregate proceeds of $18,875,341.54. The filing, a Form 144, serves as a regulatory notice of proposed or recent affiliate sales and does not specify the intended use of proceeds or details regarding a trading plan.
PACS Group Inc stock hits 52-week high at 43.11 USD
PACS Group Inc. achieved a new 52-week high of $43.11, with the stock currently trading at $43.29 and boasting a market capitalization of $6.32 billion. The company has demonstrated strong performance with a 209% one-year total return and 22% revenue growth, earning a perfect Piotroski Score of 9. Despite these positive indicators, InvestingPro analysis suggests the stock might be overvalued, providing investors with a comprehensive overview of its recent success and future considerations.
PACS Group Inks Deal For 3,600-plus Beds Across Six States -- Company Talk
PACS Group has signed an agreement to acquire a portfolio of skilled nursing facilities, totaling more than 3,600 beds across six states. This expansion signifies a major strategic move for the company in the healthcare sector. The deal aims to enhance PACS Group's presence and service delivery in the regions involved.
Price to sales forward of PACS Group, Inc. – NYSE:PACS
The article focuses on the "Price to sales forward" metric for PACS Group, Inc. (NYSE: PACS). It briefly mentions the company's financial data on the TradingView platform. The content is presented within the context of market analysis tools and financial data provision.
PACS to absorb 34 Eduro facilities in Western US
PACS Group, the nation's second-largest provider of skilled nursing and assisted living facilities, announced its acquisition of 34 skilled nursing facilities from Eduro Healthcare across six western states. This acquisition adds 3,600 beds and brings PACS's total to over 350 facilities nationwide. It marks PACS's first major acquisition since November and its largest since May 2024.
PACS Group's Acquisition Engine: Rapid Expansion Fuels Growth Amidst Mounting Risks
PACS Group continues its aggressive expansion in the post-acute healthcare sector, recently acquiring 34 facilities and reporting a significant 183% surge in net income for Q1 2026. While its growth-by-acquisition strategy has delivered impressive financial results, the company faces substantial risks due to high leverage and ongoing regulatory investigations, including those from the DOJ and SEC. Investors must weigh the potential for continued growth against the considerable financial and legal liabilities that could impact future profitability.
PACS Group to Acquire Operations of 34 Facilities Across Texas, Montana, New Mexico, North Dakota, South Dakota, and Utah
PACS Group, Inc. announced its plan to acquire the operations of 34 skilled nursing facilities from Eduro Healthcare, comprising 3,633 skilled nursing beds across six western states. The acquisition is expected to close in multiple tranches, mostly in Q3 2026, and will expand PACS Group's presence, adding four new states to its portfolio. Both companies emphasized their aligned operating models focused on local leadership empowerment and high-quality patient care.
Price to earnings forward of PACS Group, Inc. – NYSE:PACS
This page from TradingView provides financial information for PACS Group, Inc. (NYSE: PACS), specifically focusing on its forward price-to-earnings ratio. It is part of a larger financial data and market analysis platform.
Lawsuit UPDATE: Investors who hold PACS Group, Inc. (NYSE: PACS) shares should contact the Shareholders Foundation
The Shareholders Foundation, Inc. has announced that a lawsuit is pending for investors in PACS Group, Inc. (NYSE: PACS) due to alleged securities law violations. The lawsuit claims PACS Group engaged in a scheme to submit false Medicare claims, bill for unnecessary therapies, and falsify documentation, which significantly inflated its reported income. Investors who purchased shares before April 2024 and still hold them are advised to contact the Shareholders Foundation for options.
PACS Group(PACS.US) 10% Shareholder Sells US$8.08 Million in Common Stock
A 10% shareholder of PACS Group (PACS.US) has sold common stock valued at US$8.08 million. This transaction indicates a significant insider selling activity for the company.
PACS Group chief accounting officer sells $600k in stock
Michelle Renee Lewis, Chief Accounting Officer at PACS Group, Inc., sold 15,000 shares of company stock for approximately $600,178 on June 25, 2026. This transaction was part of a Rule 10b5-1 trading plan. The sale occurred as PACS stock trades near its 52-week high, with InvestingPro analysis suggesting it is overvalued despite strong financial health and positive Q1 2026 results.
Insider Sell: Mark Hancock Sells 200,000 Shares of PACS Group In
Mark Hancock, Co-Founder, Executive Vice Chairman, and 10% Owner of PACS Group Inc (PACS), sold 200,000 shares of the company on June 26, 2026. Following this transaction, Hancock now owns 54,102,597 shares. Over the past year, Hancock has sold a total of 436,320 shares, with the stock trading at $40.38 per share at the time of the recent sale.
PACS Group (PACS) co-founder Mark Hancock sells 200,000 shares
PACS Group co-founder Mark Hancock sold 200,000 shares of common stock on June 25 and 26, 2026, at an average price of $40-$41 per share, totaling over $8 million. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in March 2026. Despite the sales, Hancock retains more than 54 million shares, indicating a significant ongoing stake in the company.
PACS Group, Inc. Actuals & Estimates (NYSE:PACS)
This article provides an overview of PACS Group, Inc. (NYSE:PACS) stock performance, financial actuals, and analyst estimates. It covers the company's current stock price, historical highs and lows, market capitalization, earnings per share, revenue, net income, and future earnings report dates. The article also includes analyst forecasts and technical analysis ratings for the stock.
PACS Group (PACS) accounting chief sells 15K shares in 10b5-1 trade
PACS Group's Chief Accounting Officer, Michelle Renee Lewis, sold 15,000 shares of common stock at a weighted average price of $40.0119 per share through a pre-arranged Rule 10b5-1 trading plan. This transaction, executed on June 25, 2026, leaves Ms. Lewis with 370,338 shares directly held. The sale is considered an administrative portfolio management rather than a strong directional signal about the company, given the significant remaining holdings.
Mark Hancock sells 438,069 PACS shares across June 2026 (PACS)
Mark Hancock, a reporting person for PACS Group, Inc. (PACS), sold a total of 438,069 common shares through a series of open-market dispositions in June 2026, as detailed in a Form 144 SEC filing. These sales generated over $16 million in gross proceeds across four separate transactions. The filing also notes that Hancock initially acquired 54,626,199 shares in March 2023 at the formation of the issuer.
Form 144 | PACS Group(PACS.US) Officer Proposes to Sell 5.57 Million in Common Stocks
A PACS Group (PACS.US) officer has proposed to sell 5.57 million shares of common stock, as detailed in a recent Form 144 filing. This significant proposed sale indicates potential insider activity.
Mark Hancock sells PACS shares (PACS) — three trades in June 2026
Mark Hancock, identified as an insider, sold a total of 299,000 PACS shares across three separate transactions in mid-June 2026. The sales included 153,254 shares on June 15, 83,066 shares on June 16, and 63,680 shares on June 17, as disclosed in a Form 144 SEC filing. These transactions were recorded as common stock dispositions for cash consideration, though further details on post-transaction holdings or whether sales were part of a Rule 10b5-1 plan were not included in the filing excerpt.
PACS (NYSE) Form 144: 45,000 shares listed with J.P. Morgan
PACS Group, Inc. has filed a Form 144 notice with the SEC, indicating a proposed sale of 45,000 common shares through J.P. Morgan Securities LLC. The filing also details beneficial holdings of 1,748,250 shares and a total share count of 158,272,376 with an effective date of June 25, 2026. Additionally, the notice includes information on RSU vesting-related shares as compensation.
PACS Group (PACS) Stock Could Be 31% Below Fair Value As Expansion Draws Attention
PACS Group (PACS) is gaining investor attention due to insider share sales, rising institutional ownership, and facility expansion. While its current P/E of 24.5x is higher than peers and the industry average, a discounted cash flow (DCF) model suggests the stock could be trading at a significant discount, with an estimated future cash flow value of $55.03 per share compared to its current price of $37.77. Investors are advised to review the underlying data for a comprehensive understanding.
PACS Group co-founder Mark Hancock sells $2.25m in shares
PACS Group co-founder Mark Hancock sold approximately $2.25 million worth of company common stock on June 17, 2026, through a pre-arranged trading plan. Despite the insider sale, PACS Group's stock has surged 187% over the past year, though an InvestingPro analysis suggests it might be overvalued. The company recently reported strong Q1 2026 results, exceeding EPS expectations, and Truist Securities reiterated a Buy rating with a $52.00 price target.
Form 4 PACS Group Inc For: 22 June By Investing.com
This article announces the filing of a Form 4 for PACS Group Inc for June 22. It mentions that PACS Group Inc.'s stock (PACS) saw a 3.21% increase. The content primarily serves as a placeholder for financial news, with the bulk of the page dedicated to market data, news headlines, and an extensive navigation menu from Investing.com.
PACS Group (PACS) director Mark Hancock sells 63,680 shares under 10b5-1 plan
PACS Group director Mark Hancock sold a total of 63,680 shares of common stock on June 17, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted average prices of $35.2838 and $35.7491 per share. Following these transactions, Hancock directly holds approximately 54.3 million shares of PACS Group common stock.
PACS Group | 4: Statement of changes in beneficial ownership of securities-Officer Lewis Michelle Renee
This article is a Statement of changes in beneficial ownership of securities for Officer Lewis Michelle Renee of PACS Group. It appears to be a formal document detailing changes in stock ownership.
Could Rising Institutional Ownership Put PACS Group in the Russell 1000 Spotlight?
The article discusses the potential for PACS Group, involved in skilled nursing operations and healthcare facilities, to gain more prominence within the Russell 1000 Index. This attention is fueled by rising institutional ownership, recent positive quarterly results, and facility expansion efforts. The content highlights PACS Group's relevance to the Russell 1000 as a publicly traded mid-cap U.S. healthcare company.
Rising Institutional Stakes and Insider Selling Could Be A Game Changer For PACS Group (PACS)
PACS Group (NYS:PACS) is experiencing increased institutional ownership (32.64%) and improved financials, while insiders, including co-founder Mark Hancock, are selling shares. This dynamic presents a complex investment scenario, highlighting strong institutional confidence alongside insider diversification. The company's investment narrative focuses on growth through acquisitions and sustainable margins, supported by a $250 million share repurchase authorization.
Insider Sell: Mark Hancock Sells 236,320 Shares of PACS Group In
Mark Hancock, Co-Founder, Executive Vice Chairman, and 10% Owner of PACS Group Inc (PACS), sold 236,320 shares of the company on June 16, 2026. Following this transaction, Hancock now owns 54,366,277 shares. Over the past year, there has been one insider buy and four insider sells for PACS Group Inc, with shares trading at $36.18 each and a market cap of $5.577 billion at the time of the recent sale.
Pacs Group Inc (PACS) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes Pacs Group Inc's financial health, noting its current financial score of 8.57, which ranks 16th out of 76 in the Healthcare Providers & Services industry. The company's financial status is described as weak, although its operating efficiency is high. Key financial metrics such as cash and cash equivalents, total assets, and total liabilities have not yet been disclosed by the company.
Pacs Group Inc (PACS) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Pacs Group Inc (PACS), noting its current valuation score of 7.01, ranking 62 out of 76 in the Healthcare Providers & Services industry. It highlights the company's P/E ratio of 22.64, which is significantly below its recent high and above its recent low. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company yet.
Mark Hancock sells 236,320 PACS shares (NYSE: PACS) via Citi
Mark Hancock, an insider at PACS Group, Inc., has filed a Form 144 revealing proposed sales of 236,320 shares of PACS stock through Citigroup Global Markets Inc. The sales, occurring on June 15 and June 16, 2026, totaled approximately $8.55 million in gross proceeds. This filing serves as a notification of intended insider dispositions, with the shares originally acquired at the company's formation on March 1, 2023.
PACS Group (PACS) co-founder sells 236K shares in 10b5-1 stock plan
Mark Hancock, Co-Founder and Executive Vice Chairman of PACS Group, sold a total of 236,320 shares of company common stock in open-market transactions on June 15-16, 2026. These sales were pre-arranged under a Rule 10b5-1 trading plan adopted on March 11, 2026, with shares sold at weighted average prices between $35.90 and $37.87. Following these transactions, Hancock directly holds over 54 million shares of PACS Group common stock.
PACS Group Shareholders Back Board, Auditor and Compensation
PACS Group, Inc. shareholders demonstrated strong engagement at their 2026 Annual Meeting, electing Class II directors Evelyn Dilsaver and Mark Hancock, ratifying Ernst & Young LLP as auditor, and approving executive compensation. A recent analyst rating on PACS stock is a Buy with a $52.00 price target, though TipRanks' AI Analyst, Spark, rates it as Neutral due to balance-sheet and earnings-call risks, despite positive fundamentals. PACS Group operates in the healthcare sector, providing post-acute care services.
Pacs Group Inc (PACS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Pacs Group Inc (PACS) stock, focusing on its dividends and stock splits. It notes that PACS has distributed $0.00 in dividends over the past five years and currently has no recorded stock splits. The article also includes current stock price data, market capitalization, and P/E ratio for Pacs Group Inc.
Pacs Group Inc (PACS) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Pacs Group Inc (PACS), highlighting its current earnings forecast score of 8.67, ranking 8th in its industry. Analysts have set an average price target of $32.50 for PACS, with most analysts recommending a "Buy" rating. The report also details expected revenue, EPS, and provides a peer comparison in the Healthcare Providers & Services industry.
[144] PACS Group, Inc. SEC Filing
This article details an SEC Form 144 filing by PACS Group, Inc., specifically for a proposed sale of securities under Rule 144 of the Securities Act of 1933. The filing indicates a significant number of common shares to be sold, valued at over $5.5 million, by Citigroup Global Markets Inc. on the NYSE, originating from shares acquired at the issuer's formation.
PACS Group Inc (PACS) Receives a Buy from Truist Financial
Truist Financial analyst Jailendra Singh reiterated a Buy rating for PACS Group Inc (PACS) and set a price target of $52.00. The company reported strong financial results for the quarter ending March 31, with revenues of $1.42 billion and a net profit of $80.7 million. Despite negative insider sentiment with recent share sales, the overall analyst consensus for PACS Group Inc is a Strong Buy.
Truist reiterates Buy on PACS Group stock citing strong demand
Truist Securities has reiterated a Buy rating on PACS Group (NYSE:PACS) with a $52.00 price target, citing strong demand and the company's robust clinical and operational execution. PACS Group has shown a remarkable 252% return over the past year and boasts strong financial health with a Piotroski Score of 9. The firm highlighted PACS's financial flexibility, strong liquidity, minimal leverage, and brisk cash flow, anticipating continued investment, execution, and M&A opportunities.
PACS Group (NYSE: PACS) stockholders back all 2026 annual meeting proposals
PACS Group, Inc. reported that its stockholders approved all proposals at the 2026 Annual Meeting, held on June 10, 2026. This included the election of Evelyn Dilsaver and Mark Hancock as Class II directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm, and the advisory approval of named executive officer compensation. Shareholder participation was very high, with approximately 97.33% of outstanding shares represented.
PACS Group, Inc. (PACS) director Evelyn Dilsaver awarded 4,660 RSUs
PACS Group, Inc. director Evelyn S. Dilsaver was granted 4,660 restricted stock units (RSUs) as equity compensation, with each RSU converting to one share upon vesting. The RSUs will vest 100% on the earlier of June 10, 2027, or the next annual meeting, subject to her continued service. Following this grant, Dilsaver directly holds 31,798 shares of Common Stock.
Director at PACS Group (PACS) receives 4,660 restricted stock units award
Patrick Hugh Conway, a director at PACS Group, Inc. (PACS), was granted 4,660 restricted stock units (RSUs), bringing his total holdings to 8,157 shares. These RSUs will vest 100% on the earlier of June 10, 2027, or the next annual meeting, provided he continues his service to the company. This equity award, classified as a grant (transaction code A), was not an open-market purchase.
PACS Group (PACS) director awarded 4,660 restricted stock units in Form 4
PACS Group, Inc. director Taylor S. Leavitt was granted 4,660 restricted stock units (RSUs) as compensation, convertible into common stock upon vesting. This award is distinct from an open-market purchase or sale and increases Leavitt's direct holdings to 15,497 shares. The RSUs are set to vest 100% on the earlier of June 10, 2027, or the next annual meeting, contingent on continued service to the company.
